New molecular targets in bone metastases

https://doi.org/10.1016/S0305-7372(10)70013-XGet rights and content

SUMMARY

Bone metastases have a major impact on morbidity and on mortality in cancer patients. Despite its clinical relevance, metastasis remains the most poorly elucidated aspect of carcinogenesis. The biological mechanisms leading to bone metastasis establishment have been referred as “vicious circle,” a complex network between cancer cells and the bone microenvironment. This review is aimed to underline the new molecular targets in bone metastases management other than bisphosphonates. Different pathways or molecules such as RANK/RANKL/OPG, cathepsin K, endothelin-1, Wnt/DKK1, Src have recently emerged as potential targets and nowadays preclinical and clinical trials are underway. The results from those in the advanced clinical phases are encouraging and underlined the need to design large randomised clinical trials to validate these results in the next future.

Targeting the bone by preventing skeletal related events (SREs) and bone metastases has major clinical impact in improving survival in bone metastatic patients and in preventing disease relapse in adjuvant setting.

References (38)

  • JY Gauthier et al.

    The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K

    Bioorg Med Chem Lett

    (2008)
  • T Miyazaki et al.

    Src kinase activity is essential for osteoclast function

    J Biol Chem

    (2004)
  • MC Frame

    Src in cancer: deregulation and consequences for cell behaviour

    Biochim Biophys Acta

    (2002)
  • S Yaccoby et al.

    Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo

    Blood

    (2007)
  • M Fulciniti et al.

    Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma

    Blood

    (2009)
  • RN Kaplan et al.

    Preparing the “soil”: the premetastatic niche

    Cancer Res

    (2006)
  • CJ Logothetis et al.

    Osteoblasts in prostate cancer metastasis to bone

    Nat Rev Cancer

    (2005)
  • XH Liu et al.

    Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor-{kappa}B (RANK) ligand/RANK system

    Endocrinology

    (2005)
  • H Uehara et al.

    Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases

    J Natl Cancer Inst

    (2003)
  • Cited by (55)

    • What Are the Approaches to Pain in Skeletal Bone Disease?

      2023, Evidence-Based Practice of Palliative Medicine, Second Edition
    • Changing landscape of optical imaging in skeletal metastases

      2019, Journal of Bone Oncology
      Citation Excerpt :

      Inhibition of the receptor not only prevents migration of MM cells, but also sensitizes malignant tumor cells to therapeutic agents [86]. Tumor Growth Factor-β (TGF-ß) and RANKL are two prominent soluble factors involved in stimulation of pro-osteoclast formation [87]. RANKL activates osteoclast-mediated bone resorption and subsequently promotes the release of matrix growth factors such as TGF-ß, further inducing tumor growth in a positive feedback mechanism [87].

    • 3D printing hydrogel with graphene oxide is functional in cartilage protection by influencing the signal pathway of Rank/Rankl/OPG

      2018, Materials Science and Engineering C
      Citation Excerpt :

      One essential characteristic of GO-np is their hydrophobic domains within the core, which are substantially ionized along the edges and then GO-np can have large specific surface area, strong ion exchange capacity, therefore, having a high drug-loading capacity [20,21]. Presenting itself as a candidate for osteoclastogenesis, rank plays a central role in the pathway of Rank/Rankl/OPG, they can regulate OPG and Rankl via direct interaction in the Rank/Rankl/OPG system [22,23]. Rank is also known as TNF-related activation-induced cytokine receptor since its signaling plays a critical role in osteoclastogenesis [23].

    • Assessing response to treatment of bone metastases from breast cancer: What should be the standard of care?

      2015, Annals of Oncology
      Citation Excerpt :

      The bone marrow also provides an ideal milieu with low partial pressures of oxygen and pH as well as high levels of extracellular calcium which promote residence and dormancy of DTCs [4, 5]. Once metastatic colonization from CICs is initiated, the normal balanced homeostatic mechanisms of bone formation and resorption, the RANK-RANKL homeostatic loop between osteoblasts and osteoclasts, becomes disrupted [6]. The binding of these two tumour necrosis factor proteins drives bone resorption by osteoclasts; this binding is regulated by the expression of the decoy receptor osteoprotegerin (OPG) [7].

    View all citing articles on Scopus
    View full text